APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Grossi Federico V.; Bedwell Pauline; Deschatelets Pascal; Edis Lil; Francois Cedric G.; Johnson Patrick J.; Richardson Helen J.; Tan Lisa; Vega Carolina A.; Lickliter Jason

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

【24h】

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

机译：APL-2，一种用于潜在治疗阵发性夜间血红蛋白尿（PNH）的补体C3抑制剂：两项来自健康志愿者的完整研究的I期数据

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共4页
作者
Grossi Federico V.; Bedwell Pauline; Deschatelets Pascal; Edis Lil; Francois Cedric G.; Johnson Patrick J.; Richardson Helen J.; Tan Lisa; Vega Carolina A.; Lickliter Jason;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers [J] . Grossi Federico V., Bedwell Pauline, Deschatelets Pascal, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：APL-2，一种用于潜在治疗阵发性夜间血红蛋白尿（PNH）的补体C3抑制剂：两项来自健康志愿者的完整研究的I期数据
2. APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria [J] . Delphine El Mehdi, Federico V. Grossi, Pascal Deschatelets, Molecular Immunology . 2017,第期

机译：APL-2，一种补体C3抑制剂，可能会潜在地减少阵发性夜间血红蛋白尿的患者血管内和血管外溶血
3. Topline-Results indicate the Success of the two Phase-3-ALXN1210 Clinical Trials in Complement Inhibitor Treatment-Naive Patients with paroxysmal nocturnal Hemoglobinuria (PNH) and those previously treated with Soliris (R) (Eculizumab) [J] . Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur? Transfusionsmedizin und Immunham?atologie . 2018,第4期

机译：Topline-结果表明，两相3-ALXN1210临床试验中的补体抑制剂治疗 - 天真患者的临床试验，患有索昔肠杆菌（PNH）和先前用Soliris（r）（ar）（eculizumab）治疗的患者
4. The study on RBC characteristic in paroxysmal nocturnal hemoglobinuria (PNH) patients using common path interferometric quantitative phase microscopy [C] . Byung Jun Park, Youngjae Won, Byungyeon Kim, Quantitative phase imaging II . 2016

机译：阵发性夜间血红蛋白尿（PNH）患者的RBC特征的共路径干涉定量相显微镜研究
5. Synthesis of Bivalent Organothiophosphate Inhibitors and Their Inhibition of Butyrylcholinesterase: Studies towards a Potential Treatment of Cognitive Loss Associated with Alzheimer's Disease [D] . Tahira, Ambreen. 2017

机译：二价有机硫代磷酸酯抑制剂的合成及其对丁酰胆碱酯酶的抑制：潜在治疗与阿尔茨海默氏病相关的认知丧失的研究
6. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. [O] . W F Rosse, J V Dacie 1966

机译：正常人和阵发性夜间血红蛋白尿（PNH）红细胞的免疫裂解。 I. PNH红细胞对补体和特异性抗体裂解的敏感性。
7. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. [O] . Risitano AM, Ricklin D, Huang Y, 2014

机译：C3激活的肽抑制剂作为补体抑制的新策略用于治疗阵发性睡眠性血红蛋白尿。

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

著录项

相似文献

相关主题

期刊订阅